JNCE Jounce Therapeutics Inc.

5.07
0  0%
Previous Close 5.07
Open 5.03
Price To Book 1.77
Market Cap 167169789
Shares 32,972,345
Volume 65,568
Short Ratio
Av. Daily Volume 213,119

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data at AACR - PFS: median 6.2 months for patients with ICOS hi CD4 T cells.
JTX-2011
Solid tumors - Cancer
Phase 1 enrolment to be completed in 2019.
JTX-4014
Solid tumors
Phase 2 initial data due 2020.
Vopratelimab (JTX-2011) + ipilimumab
Bladder cancer
Phase 2 initial data due 2020.
Vopratelimab (JTX-2011) + ipilimumab
Non-small cell lung cancer and bladder cancer

Latest News

  1. Edited Transcript of JNCE.O earnings conference call or presentation 8-May-19 12:00pm GMT
  2. Jounce Therapeutics, Inc. (JNCE) Reports Q1 Loss, Misses Revenue Estimates
  3. Jounce Therapeutics Reports First Quarter 2019 Financial Results
  4. Will Jounce Therapeutics, Inc. (JNCE) Report Negative Q1 Earnings? What You Should Know
  5. Jounce Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019
  6. Here's Why Jounce Therapeutics Rose 39.3% in March
  7. Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the 2019 American Association for Cancer Research (AACR) Annual Meeting
  8. Jounce Therapeutics Reports Improved PFS and OS Associated with Vopratelimab (JTX-2011) Treatment Emergent Biomarker at the 2019 American Association for Cancer Research (AACR) Annual Meeting
  9. Investors Who Bought Jounce Therapeutics (NASDAQ:JNCE) Shares A Year Ago Are Now Down 80%
  10. Edited Transcript of JNCE.O earnings conference call or presentation 6-Mar-19 1:00pm GMT
  11. Jounce Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
  12. Jounce Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference
  13. Jounce Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Wednesday, March 6, 2019
  14. Jounce Therapeutics to Present Data from its JTX-2011 and JTX-8064 Programs at the 2019 American Association for Cancer Research (AACR) Annual Meeting
  15. In-house lawyers demand diversity, but their own boards lack women
  16. Edited Transcript of JNCE.O earnings conference call or presentation 13-Nov-18 1:00pm GMT
  17. Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014
  18. Jounce Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
  19. Hedge Funds Are Crazy About Jounce Therapeutics, Inc. (JNCE)